Clinical Trials Logo
  1. Home
  2. Cystic Fibrosis
  3. NCT02734810
  4. Details
NCT02734810 Clinical Trial

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis

Cystic Fibrosis Clinical Trial

— SIMPLICITY  

Official title:
A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02734810
Other study ID # AN-EPI3332
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date June 2016
Est. completion date March 2017

Study information
Verified date April 2018
Source Anthera Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Liprotamase consists of 3 soluble, non-porcine digestive enzymes, lipase, protease, and amylase, combined in a fixed ratio. Liprotamase is stable in the stomach and can be formulated without enteric coating for administration either as a capsule or as a dosing solution dissolved in water or juice. The purpose of the present study is to provide efficacy and safety data for a new, soluble formulation of liprotamase, Liprotamase Powder for Oral Solution, in Cystic Fibrosis patients with exocrine pancreatic insufficiency (EPI).

Recruitment information / eligibility
Status Completed
Enrollment 15
Est. completion date March 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- For Part A: males or females =7 years of age

- For Part B: males or females 28 days to <7 years

- Diagnosis of cystic fibrosis based on presentation, genotype and/or sweat chloride

- Low fecal elastase

- Fair-to-good nutritional status

Exclusion Criteria:

- History or diagnosis of fibrosing colonopathy

- Distal intestinal obstruction syndrome in 6 months prior to screening

- Receiving enteral tube feedings

- Chronic diarrheal illness unrelated to pancreatic insufficiency

- Liver abnormalities, or liver or lung transplant, or significant bowel resection

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Liprotamase Powder for Oral Solution
Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy

Locations
Country Name City State
United States Investigator Site 117 Altamonte Springs Florida
United States Investigator Site 124 Ann Arbor Michigan
United States Investigator Site 110 Atlanta Georgia
United States Investigator Site 114 Aurora Colorado
United States Investigator Site 111 Dallas Texas
United States Investigator Site 118 Durham North Carolina
United States Investigator Site 109 Glenview Illinois
United States Investigator Site 106 Hershey Pennsylvania
United States Investigator Site 138 Hollywood Florida
United States Investigator Site 116 Houston Texas
United States Investigator Site 135 Las Vegas Nevada
United States Investigator Site 139 Little Rock Arkansas
United States Investigator Site 122 Louisville Kentucky
United States Investigator Site 130 Miami Florida
United States Investigator Site 129 Morgantown West Virginia
United States Investigator Site 101 Oklahoma City Oklahoma
United States Investigator Site 136 Oklahoma City Oklahoma
United States Investigator Site Orange California
United States Investigator Site 132 Portland Maine
United States Investigator Site 112 Richmond Virginia
United States Investigator Site 105 Wichita Kansas

Sponsors (1)
Lead Sponsor Collaborator
Anthera Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Safety Number of subjects reporting 1 or more adverse events 1 week
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A